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Article

Comparative Effectiveness of Two Catheter Locking
Solutions to Reduce Catheter-Related Bloodstream
Infection in Hemodialysis Patients
Carol L. Moore,*† Anatole Besarab,‡ Marie Ajluni,§ Vivek Soi,* Edward L. Peterson,| Laura E. Johnson,§¶
Marcus J. Zervos,§¶** Elizabeth Adams,* and Jerry Yee*

Abstract
Background and objectives Infection is the second leading cause of death in hemodialysis patients. Catheterrelated bloodstream infection and infection-related mortality have not improved in this population over the past
two decades. This study evaluated the impact of a prophylactic antibiotic lock solution on the incidence of
catheter-related bloodstream infection and mortality.
Design, setting, participants, & measurements This prospective, multicenter, observational cohort study
compared the effectiveness of two catheter locking solutions (gentamicin/citrate versus heparin) in 555
hemodialysis patients dialyzing with a tunneled cuffed catheter between 2008 and 2011. The groups were not
mutually exclusive. Rates of catheter-related bloodstream infection and mortality hazards were compared
between groups.
Results The study population (n=555 and 1350 catheters) had a median age of 62 years (interquartile range=41–83
years), with 50% men and 71% black. There were 427 patients evaluable in the heparin period (84,326 days)
and 322 patients evaluable in the antibiotic lock period (71,192 days). Catheter-related bloodstream infection
in the antibiotic lock period (0.45/1000 catheter days) was 73% lower than the heparin period (1.68/1000 catheter
days; P=0.001). Antibiotic lock use was associated with a decreased risk of catheter-related bloodstream infection
compared with heparin (risk ratio, 0.23; 95% conﬁdence interval, 0.13 to 0.38 after multivariate adjustment).
Cox proportional hazards modeling found that antibiotic lock was associated with a reduction in mortality
(hazard ratio, 0.36; 95% conﬁdence interval, 0.22 to 0.58 in unadjusted analyses; hazard ratio, 0.32; 95% conﬁdence interval, 0.14 to 0.75 after multivariate adjustment). The rate of gentamicin-resistant organisms decreased
(0.40/1000 person-years to 0.22/1000 person-years) in the antibiotic lock period (P=0.01).
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Conclusions The results of this study show that the use of a prophylactic, gentamicin/citrate lock was associated
with a substantial reduction in catheter-related bloodstream infection and is the ﬁrst to report a survival
advantage of antibiotic lock in a population at high risk of infection-related morbidity and mortality.
Clin J Am Soc Nephrol 9: 1232–1239, 2014. doi: 10.2215/CJN.11291113

Introduction
Over 370,000 patients undergo maintenance hemodialysis in the United States, with up to 80% initiating
with a central venous catheter (1). Recent data from
the Centers for Medicare and Medicaid Services
(CMS) show that the overall prevalence of catheter
use is 29%; however, the prevalence is as high as
69% in the ﬁrst 6 months of dialysis and as high as
41% at the end of the ﬁrst 1 year (2). There is general
consensus that use of catheters as opposed to permanent arteriovenous ﬁstulae or grafts contributes to
excessive mortality not only during this period but
throughout a patient’s course on hemodialysis. The
rate of catheter-related bloodstream infection (CRBSI)
reported in the literature varies, with rates from 2.5 to
6.6 per 1000 catheter days reported (3–7). The Centers
for Disease Control and Prevention (CDC) reports
1232
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that CRBSI rates have remained steady in hemodialysis patients over the last decade, with an estimated
37,000 CRBSIs occurring in 2008 (8). Overall, there
has been a reduction in all-cause mortality over the
past three decades in hemodialysis patients; however,
the rate of infection-related mortality has remained
steady (9,10).
Many randomized, controlled studies have conﬁrmed that a prophylactic antimicrobial lock strategy
reduces the incidence of CRBSI, and it has been
suggested that, for every four patients treated with
antimicrobial lock, one CRBSI is prevented (11–15).
Furthermore, two small randomized, controlled trials
showed a reduction in mortality on crude analysis by
use of a prophylactic antimicrobial lock solution
(16,17). However, this approach has not been widely
adopted. In fact, the CDC and the Infectious Diseases
www.cjasn.org Vol 9 July, 2014
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Society of America do not recommend the routine use of
these solutions and suggest reserving this treatment for
those patients with a history of multiple CRBSIs, citing
concerns for the potential emergence of antimicrobial resistance associated with the agent used (18). We conducted
the present study to evaluate the clinical outcomes associated with antimicrobial lock therapy, including CRBSI and
mortality, and to better characterize the safety implications, particularly antimicrobial resistance, in a hemodialysis population with a high incidence of CRBSI.

Materials and Methods
Study Population
This prospective, multicenter, observational cohort study
compared two locking solutions (heparin versus gentamicin/trisodium citrate) on the incidence of CRBSI and mortality in chronic hemodialysis patients dialyzing with
permanent tunneled cuffed catheters (TCCs). This study
evaluated a cross-over from heparin (control) to gentamicin/trisodium citrate (lock) in patients dialyzing with a TCC
during the period from September 1, 2008, to June 1, 2011 in
three outpatient hemodialysis centers in the Detroit metropolitan area. The cross-over occurred on October 1, 2009,
in center A, October 13, 2010, in center B, and November 10,
2010, in center C. To be included, patients had to have their
catheter placement and follow-up by the vascular surgery
department within the Henry Ford Health System. Each
patient was followed for the duration that a TCC was their
primary vascular access until a TCC was no longer medically necessary, the patient died or transferred out of the
unit, or censorship at the end of the study period. If a patient
spanned both treatment periods, the time period for followup was recorded and allocated to its appropriate locking
solution group. Each catheter was followed from the time of
placement until a CRBSI, removal for other reasons (clotting, malfunction, or no longer medically necessary), the
patient died or transferred out of unit, or censorship at the
end of the study period. If a catheter spanned both treatment
periods, the time period for each solution was recorded and
allocated to its appropriate locking solution group. Patients
were excluded if they were less than 18 years of age, were
pregnant or lactating, had known allergy or contraindication to heparin or gentamicin, or were currently being
treated for a CRBSI at time of enrollment (a lapse interval of
14 days was required between last administration of
antibiotic and enrollment). Catheters that were locked
chronically with tissue plasminogen activator (t-PA) at
any time during the control or lock period were excluded
from the analysis. This study was approved by the Institutional Review Board at Henry Ford Hospital with a
waiver of informed consent and conducted in adherence to
the Declaration of Helsinki.
Catheter Maintenance Protocols
Catheter care in the three units followed established
policies and procedures related to hemodialysis initiation, discontinuation, dressing changes, and exit site care
over the duration of the study. Standard precautions
using aseptic technique were followed, including masking of the patient and staff in addition to the staff wearing
face shields, gowns, and clean gloves. Disinfection of the
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catheter ports was performed at the start of hemodialysis
by using two gauze pads soaked in chlorine (Alcavis). One
gauze pad was used to rub the catheter port caps and
connection sites, and one gauze pad was used to soak the
catheter hubs for 2 minutes. Catheter dressing changes
were performed at each hemodialysis session and included
visual inspection and cleansing of the exit site with
chlorhexidine (3.15%). After it was dry, triple antibiotic
ointment (containing bacitracin, neomycin, and polymyxin
B) was applied to the exit site, and a sterile dry gauze
dressing was applied (19). All care was directed by the
patient’s treating nephrologist, including management of
infections and catheter malfunction and the need for catheter removal or exchange. The procedures followed for
catheter insertion and exchange by the vascular surgery
department within the Henry Ford Health System did not
change over the study period (20).
Catheter Locking Solutions
The two locking solutions evaluated were heparin (1000
units/ml) and a gentamicin/citrate antibiotic solution (0.32
mg/ml gentamicin in 4% trisodium citrate) (21). The antibiotic lock solution was prepared by either the inpatient
pharmacy or an afﬁliated home infusion pharmacy under
sterile conditions (22,23). The locking solution was instilled in a volume sufﬁcient to ﬁll each catheter lumen
at the end of dialysis and aspirated at the next dialysis
session before connection.
Data and Definitions
Study data were collected on patients from September 1,
2008, to June 1, 2011. Study data were extracted from the
medical record using a standardized case report form.
Comorbid conditions were collected from both the medical
record and the CMS Form 2728. Data collected on each
catheter included insertion and removal indication and
date, procedure for placement (guide wire exchange or
new tunnel), location of placement, bloodstream infection
in the previous 90 days, and outcome at end of catheter
follow-up. A catheter was classiﬁed by the locking solution
used. If the same catheter was exposed to both solutions
over the duration of the study, the time period for each
solution was recorded and subsequently allocated to its
appropriate locking solution group. For catheters in place
at study initiation (September 1, 2008), the age of the
catheter was also recorded. Laboratory data were collected
at study enrollment, and monthly averages were calculated for the time period that the patient was using a TCC.
We determined all-cause mortality and hospitalizations
based on death dates and hospitalization dates, which
were recorded prospectively by each dialysis center.
Each bloodstream infection was evaluated by the same
Infection Prevention Specialist as part of routine surveillance activities. Criteria established by the CDC were used
to classify an infection as a CRBSI (24). In summary, the
patient must have had an indwelling TCC, a recognized
pathogen (e.g., Staphylococcus aureus, Enterococcus spp., or
Escherichia coli) cultured from one or more blood cultures
(collected peripherally or through the dialysis circuit), and
no other source of infection. Alternatively, a patient with
an indwelling TCC must have one or more of fever
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(.38°), chills, or hypotension when growing a common
skin commensal (e.g., coagulase negative staphylococci)
from two or more blood cultures drawn on separate occasions (collected within 2 days of each other).
Safety
In vitro gentamicin susceptibility testing was conducted on
each isolate using automated microdilution with Vitek 2
(bioMerieux, Durham, NC) by the microbiology laboratory
at Henry Ford Hospital. Isolates with intermediate resistance to gentamicin were classiﬁed as resistant. Catheter
lifespan, vascular access procedures, and use of t-PA for
the purpose of establishing catheter patency were recorded.
Statistical Analyses
The two groups, heparin and antibiotic lock, were not
mutually exclusive. For this reason, a generalized estimating equations approach was used to test the various
demographic characteristics (25). The laboratory mean values were calculated and compared using ratio estimators
(26). A negative binomial model was used to compare the
rate of CRBSI between the two time periods (27). The negative
binomial model was needed, because individual patients
could have multiple occurrences of CRBSI over the study period. A log time of catheter use was used as an offset in the
model. To examine death, a Cox proportional hazards model
with a time-dependent covariate for group membership was
used. In both the negative binomial and Cox model, a univariate model with just the antibiotic lock variable and a multivariate model adding covariates were examined. Safety

characteristics were modeled with a ratio estimator approach
for all of the variables except catheter lifespan, which was
analyzed with a Kaplan–Meier approach. Data were analyzed
using SAS software, version 9.1 (SAS Institute).

Results
Study Population
Overall, 594 patients received dialysis through a TCC
during the study period. Thirty-nine patients were excluded,
because they did not have their catheters placed by vascular
surgery at the Henry Ford Health System. The overall study
population (n=555, 93% of all TCC-requiring patients and
1350 catheters) had a median age of 62 years (interquartile
range=41–83); 50% were men, 71% were black, 21% were
Caucasian, and 7% were of other ethnicity. There were 427
evaluable patients in the heparin period (84,326 days of exposure) and 322 evaluable patients in the antibiotic lock period
(71,192 days). There were 233 individual patients in the heparin period, 128 patients in the antibiotic lock period, and 194
patients who spanned both periods. Baseline demographics
and laboratory values are presented in Table 1. The populations were similar, with the exception of more black patients
in the antibiotic lock period (70% versus 75%, P=0.04).
Clinical Outcomes
There were a total of 174 CRBSIs over the study period:
142 CRBSIs in the heparin period and 32 CRBSIs in the
antibiotic lock period (Tables 2 and 3). The rate of CRBSI in
the antibiotic lock period (0.45/1000 catheter days) was

Table 1. Baseline characteristics according to catheter locking agent

Variable

Heparin (n=427)

Antibiotic Lock (n=322)

P Value

Age, yr
Women
Race (black)
Dialysis vintage, mo
Heart failure
Coronary artery disease
Other heart disease
Cerebral vascular disease
Peripheral vascular disease
Hypertension
Diabetes
COPD
Smoker
Cancer
Alcohol dependence
Drug dependence
Albumin, g/dl
Calcium (corrected), mg/dl
Phosphorus, mg/dl
Creatinine, mg/dl
Hemoglobin, g/dl
Iron saturation, %
Ferritin, ng/ml
White blood cells, K/ml

62615
213 (50%)
299 (70%)
27648
262 (61%)
151 (35%)
209 (49%)
90 (21%)
70 (16%)
413 (97%)
278 (65%)
101 (24%)
75 (18%)
76 (18%)
7 (2%)
7 (2%)
3.660.6
9.260.7
4.961.5
7.064.6
11.261.1
29610
5666418
7.062.8

62615
164 (51%)
241 (75%)
33648
189 (59%)
115 (36%)
148 (46%)
62 (19%)
51 (16%)
311 (97%)
203 (63%)
74 (23%)
65 (20%)
57 (18%)
5 (2%)
8 (3%)
3.760.4
9.260.6
5.061.0
7.562.9
11.160.8
2966
5756273
6.962.0

0.67
0.73
0.04
0.13
0.49
0.76
0.28
0.42
0.89
0.94
0.42
0.89
0.08
0.74
0.77
0.24
0.09
0.39
0.63
0.08
0.18
0.74
0.75
0.35

Values are n (%); mean6SD.
COPD, chronic obstructive pulmonary disease.
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Table 2. Clinical outcomes and safety end points according to catheter locking agent

P Value

Variable

Heparin (n=427)

Antibiotic Lock (n=322)

Observation period, d
Clinical outcomes
Episodes of CRBSI
CRBSI/1000 catheter d
Death (all cause)
Hospitalizations per patient-yr
Indications for hospitalization per patient-yr
Infection
Cardiovascular
Other
Safety end points
t-PA use per patient-yr
Gentamicin-resistant organisms/1000 patient-yr
Average catheter lifespan, d
Vascular procedures per patient-yr
Infection
Malfunction/clotting

84,326

71,192

142
1.6863.28
77 (18%)
3.563.6

32
0.4561.56
31 (10%)
3.063.1

0.001
0.001
0.06

1.361.7
0.661.3
1.161.5

0.963.1
0.961.7
0.961.2

0.001
0.09
0.28

8614
0.40
1226144
3.763.3
1.061.6
1.162.5

6615
0.22
1696231
3.563.6
0.360.9
1.462.9

0.34
0.01
0.42
0.46
0.001
0.11

CRBSI, catheter-related bloodstream infection; t-PA, tissue plasminogen activator.

Table 3. Pathogens-causing catheter-related bloodstream infection according to locking agent

Bacterial Pathogensa

Heparin

Antibiotic Lock

Gram-positive
Methicillin-resistant S. aureus
Methicillin-susceptible S. aureus
S. epidermidis
Other coagulase-negative staphylococci
Enterococcus spp. (vancomycin-susceptible)
Enterococcus spp. (vancomycin-resistant)
Other Gram-positive
Gram-negative
E. coli
Serratia spp.
Proteus spp.
Enterobacter spp.
Pseudomonas spp.
Stenotrophomonas
Klebsiella spp.
Acinetobacter spp.
Other Gram-negative
Polymicrobial
Fungal
Candida albicans
Candida glabrata
Other Candida spp.

105 (74%)
7 (5%)
18 (13%)
47 (33%)
1 (1%)
22 (16%)
4 (3%)
9 (6%)
56 (39%)
10 (7%)
5 (4%)
2 (1%)
17 (12%)
5 (4%)
5 (4%)
15 (11%)
0 (0%)
8 (6%)
29 (20%)
0 (0%)
0 (0%)
0 (0%)
0 (0%)

24 (75%)
4 (13%)
7 (22%)
4 (13%)
0 (0%)
6 (19%)
1 (3%)
2 (6%)
8 (25%)
1 (3%)
1 (3%)
1 (3%)
1 (3%)
2 (6%)
0 (0%)
0 (0%)
1 (3%)
1 (3%)
2 (6%)
2 (6%)
0 (0%)
0 (0%)
2 (6%)

a

In total, 176 pathogens were identiﬁed in 142 CRBSI episodes during the heparin period, and 34 pathogens were identiﬁed in 32 CRBSI
episodes during the antibiotic lock period.

73% lower than in the heparin period (1.68/1000 catheter
days; P=0.001). The reduction in CRBSI coincided temporally with implementation of antibiotic lock therapy (Figure 1). Use of the antibiotic lock was associated with a
decreased risk of CRBSI compared with heparin lock
(risk ratio [RR], 0.17; 95% conﬁdence interval [95% CI],
0.10 to 0.29); this decreased risk remained signiﬁcant after
multivariate adjustment (adjusted RR, 0.23; 95% CI, 0.13 to

0.38) (Table 4). The attributable risk of heparin contributing to CRBSI was 51.7%. The risk of CRBSI was signiﬁcantly increased in patients with coronary artery disease
(adjusted RR, 1.82; 95% CI, 1.07 to 3.10) and femoral placement of the TCC (adjusted RR, 5.84; 95% CI, 1.84 to 18.55).
There were 77 deaths during the heparin period and 31
deaths during the antibiotic lock period (18% versus 10%;
P=0.001) (Figure 2). Cox proportional hazards modeling found
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Figure 1. | Quarterly CRBSI rates pre- and postimplementation of antibiotic lock therapy. Error bars show the 95% confidence interval of the
estimate. CRBSI, catheter-related bloodstream infection.

Table 4. Multivariate modeling for catheter-related bloodstream infection

Variable

Adjusted Risk Ratio (95% CI)

P Value

Antibiotic lock
Age, yr
Women
Race (black)
Dialysis vintage, mo
Heart failure
Coronary artery disease
Other heart disease
Cerebral vascular disease
Peripheral vascular disease
Hypertension
Diabetes
COPD
Smoker
Cancer
Alcohol dependence
Drug dependence
Catheter placement (new tunnel)a
Catheter location (femoral)b
Catheter length, cm

0.23 (0.13 to 0.38)
1.15 (0.99 to 1.35)
1.17 (0.73 to 1.89)
0.93 (0.54 to 1.62)
1.00 (0.95 to 1.05)
0.75 (0.42 to 1.35)
1.82 (1.07 to 3.10)
0.84 (0.51 to 1.38)
1.09 (0.61 to 1.94)
0.77 (0.39 to 1.51)
0.84 (0.08 to 8.30)
1.04 (0.60 to 1.80)
1.03 (0.56 to 1.92)
0.84 (0.42 to 1.66)
1.72 (0.82 to 3.60)
9.07 (0.29 to 280.08)
0.83 (0.35 to 1.95)
0.76 (0.47 to 1.22)
5.84 (1.84 to 18.55)
0.71 (0.40 to 1.27)

0.001
0.07
0.51
0.80
0.95
0.34
0.03
0.50
0.78
0.44
0.88
0.90
0.92
0.61
0.15
0.21
0.66
0.26
0.003
0.25

Risk ratios are for change of 1 for all except age and catheter length, where change was 10. A negative binomial model was used to
examine the catheter infection rates in the two groups. 95% CI, 95% conﬁdence interval; COPD, chronic obstructive pulmonary disease.
a
New tunnel versus exchange over a guide wire.
b
Catheter placement into femoral vein versus internal jugular vein.

that use of antibiotic lock was associated with a signiﬁcant reduction in mortality (hazard ratio [HR], 0.36; 95% CI, 0.22 to
0.58 in unadjusted analyses; HR, 0.32; 95% CI, 0.14 to 0.75 after
multivariate adjustment) (Table 5). The attributable risk of heparin contributing to death was 35.3%. The risk for mortality
was signiﬁcantly increased for an increased white blood
cell count (HR, 1.19; 95% CI, 1.10 to 1.29 after multivariate

adjustment) and signiﬁcantly decreased for higher albumin
(HR, 0.47; 95% CI, 0.25 to 0.86 after multivariate adjustment).
There were 883 hospitalizations during the heparin period
and 598 hospitalizations during the antibiotic lock period.
When comparing the rate of all-cause hospitalization, the rate
was 3.563.6 per person-year in the heparin period compared
with 3.063.1 per person-year in the antibiotic lock period

Clin J Am Soc Nephrol 9: 1232–1239, July, 2014
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Figure 2. | Kaplan–Meier estimates of all-cause mortality. Hazard ratio to time of death, 0.36; 95% confidence interval, 0.22 to 0.58.

Table 5. Cox proportional hazards regression analysis for all-cause mortality

Variable

Unadjusted Hazard Ratio
(95% CI)

P Value

Adjusted Hazard Ratio
(95% CI)

Antibiotic lock
Age, yr
Women
Race (black)
Dialysis vintage, mo
Heart failure
Coronary artery disease
Other heart disease
Cerebral vascular disease
Peripheral vascular disease
Hypertension
Diabetes
COPD
Smoker
Cancer
Albumin, g/dl
Calcium (corrected), mg/dl
Phosphorus, mg/dl
Creatinine, mg/dl
Hemoglobin, g/dl
Iron saturation, %
Ferritin, ng/ml
White blood cells, K/ml

0.36 (0.22 to 0.58)
1.28 (1.10 to 1.47)
1.03 (0.70 to 1.51)
0.72 (0.48 to 1.07)
0.90 (0.54 to 1.49)
1.38 (0.91 to 2.11)
1.24 (0.85 to 1.82)
1.72 (1.16 to 2.56)
1.70 (1.13 to 2.55)
1.04 (0.64 to 1.67)
0.29 (0.15 to 0.55)
0.91 (0.61 to 1.36)
1.31 (0.87 to 1.97)
0.80 (0.47 to 1.36)
1.20 (0.75 to 1.92)
0.18 (0.13 to 0.24)
1.67 (1.18 to 2.34)
0.87 (0.74 to 1.02)
0.72 (0.65 to 0.80)
0.67 (0.58 to 0.78)
1.14 (0.93 to 1.38)
2.11 (1.43 to 3.12)
1.18 (1.14 to 1.21)

0.001
0.001
0.89
0.10
0.69
0.13
0.27
0.007
0.01
0.88
0.001
0.65
0.21
0.41
0.45
0.001
0.003
0.09
0.001
0.001
0.20
0.001
0.001

0.32 (0.14 to 0.75)
1.05 (0.79 to 1.38)
0.74 (0.38 to 1.44)
0.94 (0.47 to 1.88)
1.93 (0.98 to 3.81)
1.08 (0.48 to 2.45)
0.88 (0.93 to 1.81)
2.12 (0.99 to 4.54)
1.00 (0.49 to 2.03)
0.91 (0.40 to 2.08)
0.47 (0.15 to 1.50)
0.94 (0.47 to 1.89)
1.53 (0.77 to 3.04)
0.65 (0.26 to 1.63)
0.97 (0.46 to 2.06)
0.47 (0.25 to 0.86)
1.28 (0.88 to 1.87)
1.20 (0.92 to 1.57)
0.83 (0.68 to 1.00)
0.87 (0.69 to 1.10)
1.12 (0.90 to 1.40)
1.04 (0.69 to 1.58)
1.19 (1.10 to 1.29)

P Value
0.008
0.73
0.37
0.85
0.06
0.85
0.73
0.05
.0.99
0.82
0.20
0.86
0.23
0.36
0.94
0.01
0.20
0.17
0.05
0.24
0.34
0.85
0.001

Hazard ratios are for change of 1 for all except age and iron saturation, where change was 10. COPD, chronic obstructive pulmonary disease.

(P=0.06). When comparing the rate of infection-related hospitalization, the rate was 1.361.7 per person-year in the heparin period compared with 0.963.1 per person-year in the
antibiotic lock period (P=0.001).
Safety End Points
When comparing the gentamicin resistance rates, the
rate decreased from 0.40/1000 person-years in the heparin period to 0.22/1000 person-years in the antibiotic lock

period (P=0.01). There were 28 resistant organisms in the
control period: 21 (75%) organisms were Gram-positive,
and 7 (25%) organisms were Gram-negative. There were
15 resistant organisms in the antibiotic lock period: 10
(67%) organisms were Gram-positive, and 5 (33%) organisms were Gram-negative. Particularly, the gentamicinresistant organisms occurring in the heparin period include
methicillin-resistant S. aureus (2), Staphylococcus epidermidis (11), Enterococcus spp. (28), E. coli (10), Klebsiella
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spp. (2), and other Gram-negative (1) organisms. The gentamicinresistant organisms occurring in the antibiotic lock period
include methicillin-resistant S. aureus (1), S. epidermidis (9),
Enterococcus spp. (3), E. coli (1), Proteus spp. (1), Enterobacter
spp. (1), Pseudomonas spp. (1), and other Gram-negative (1)
organizations. The average catheter lifespan was 1226144
days during the heparin period compared with 1696231
days during the antibiotic lock period (P=0.42). When comparing the rate of catheter-related vascular access procedures, the rate was 3.763.3 per person-year in the heparin
period compared with 3.563.6 per person-year in the antibiotic lock period (P=0.46). The rates of vascular access procedures for infection decreased in the antibiotic lock period
(1.061.6 versus 0.360.9; P=0.001) and were similar for
malfunction/clotting (1.162.5 versus 1.462.9; P=0.11) between the two periods. The rate of t-PA administration
was 8614 per person-year for the heparin period and
6615 per person-year for the antibiotic lock period
(P=0.34). We also compared the usage of common antibiotics (vancomycin, cefazolin, and cefepime) between
the heparin and the antibiotic lock period. The geometric mean of the overall usage of the three antibiotics was
6.5 mg/d in the heparin period compared with 4.5 mg/d in
the antibiotic lock period (difference of log-transformed
data, 0.44; 95% CI, 0.10 to 0.75; P=0.01).

Discussion
This study evaluated the comparative effectiveness of
heparin and a prophylactic antibiotic lock solution on clinical
outcomes in a hemodialysis population with a high incidence
of CRBSI. Our ﬁndings conﬁrm the results of prior work,
which showed a signiﬁcant reduction in CRBSI from the use
of the same prophylactic antibiotic lock (21). Our study is the
ﬁrst to show a survival advantage associated with use of a
prophylactic, low-dose gentamicin/citrate locking solution,
conferring a 68% relative reduction in mortality after multivariate adjustment.
Infection is the second leading cause of death in hemodialysis patients, second only to cardiovascular disease.
Unfortunately, there has not been any major advancement
in the past two decades that has been successful in reducing
either infection-related morbidity or mortality in this patient
population. Although we did not ﬁnd a signiﬁcant reduction
in overall hospitalization rates by use of antibiotic lock, we
did ﬁnd a signiﬁcant reduction (31%) in infection-related
hospitalizations in the antibiotic lock period. In an era
when infection-related hospitalizations in dialysis patients are up 43% over the past two decades and much
focus is on reducing preventable healthcare use, a safe
and effective intervention that could reduce this burden is
desirable (1).
A major concern in using gentamicin as a catheter locking
agent is the emergence of resistant organisms. This is a major
concern for the CDC and the primary reason for the lack of a
recommendation for the routine use of any prophylactic
antibiotic lock, because studies showing efﬁcacy in reducing
CRBSI are numerous (11–15). Most studies evaluating efﬁcacy of antibiotic lock have been of small size and/or short
duration, not allowing for the ability to evaluate antibiotic
resistance over longer periods of time or in a real world
setting. A recent study reported a 95% reduction in CRBSI

(17–0.83/1000 catheter days) in over 1400 patients by use
of a prophylactic gentamicin/heparin lock (29). This study
reported that the presence of gentamicin-resistant organisms over 4 years of use of the lock led to cessation of the
lock protocol. However, the study lacked susceptibility data
for the period before implementing the lock; therefore, it is
not known if gentamicin resistance patterns actually
changed after initiation of the lock or were similar to the
patterns seen before using the lock. A randomized, controlled trial using the same prophylactic, low-dose lock as
the current study found stable gentamicin susceptibility patterns over the 5-year course of the study in both treatment
groups (21). Our study found that gentamicin resistance
was present during the control period and that the incidence signiﬁcantly decreased in the antibiotic lock period.
This ﬁnding could be related to the lower dose of gentamicin used in the lock solution or the use of citrate as opposed
to heparin, because heparin has been shown to increase
bioﬁlm production, which in turn, can increase antimicrobial resistance (30,31). Although the number of gentamicinresistant organisms is relatively small, we did not ﬁnd that
speciﬁc organisms, particularly S. aureus, were more likely
to be gentamicin-resistant after using the antibiotic lock.
Other safety end points, such as t-PA use, vascular access
procedures, and catheter lifespan, were similar between the
two periods, showing that catheter patency was also maintained during the antibiotic lock period.
Our study has certain limitations. It was a prospective,
observational study. As with any observational study, the
presence of selection bias cannot be excluded. We attempted
to control for it by collecting and adjusting for a large
number of potential confounders that could have inﬂuenced
outcome. Also, all prevalent patients dialyzing with tunneled catheters in the units were changed to prophylactic
antibiotic lock. Use of antibiotic lock was not dependent on
clinician behavior or particular patient characteristics beyond having a tunneled catheter. Importantly, there were
no identiﬁable practice pattern changes between the control
and lock periods, including the catheter maintenance protocol and procedures followed by vascular surgery. When
evaluating the incidence of CRBSI over time, there was a
direct and temporal relationship between the initiation of
antibiotic lock and a signiﬁcant reduction in CRBSI at each
dialysis unit. Despite this ﬁnding, unidentiﬁed confounders
may still be present that could have inﬂuenced outcome.
Unfortunately, we were not able to accurately determine
cause of death and, therefore, adequately assess infectionrelated mortality. Additionally, the period of follow-up for
antibiotic lock was relatively short in two of three units
(approximately 7–8 months). Important strengths of this
study include its multicenter evaluation in a large number
of hemodialysis patients and its real world evaluation in a
captured patient population, which support its generalizability. Outcomes were captured in this population, because hemodialysis units are required to prospectively
follow all vascular access-related infections, hospitalizations, and deaths. We were also able to critically evaluate
antimicrobial resistance patterns between the two treatment periods over a longer period of time, which has
been a limitation of prior work.
The results of this study show that the use of a prophylactic, low-dose gentamicin/citrate lock was associated
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with a lower rate of CRBSI, and this study is the ﬁrst to
report a signiﬁcant survival advantage of antibiotic lock in a
population at high risk of infection-related morbidity and
mortality. This study supports the prophylactic use of a
gentamicin/citrate lock in dialysis units exhibiting a higher
rate of CRBSI (.1.68/1000 catheter days) but does not assess
its use in units with lower rates of CRBSI, where its impact
would be expected to be less. Despite our ﬁnding that a gentamicin/citrate lock was safe and effective, decisions to implement this protocol should be made judiciously and only
when other standard attempts have failed to reduce rates.
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